Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MMP2 | P08253 | 5/20 | 0.62 |
| ▸ | ANPEP | P15144 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551113 | 1.00 | KMT2A (0.64) | KMT2AALDH1A1MMP2ANPEPMEN1 | |
| SCHEMBL2227030 | 1.00 | KMT2A (0.64) | KMT2AALDH1A1MMP2ANPEPMEN1 | |
| SCHEMBL12317084 | 0.90 | ALDH1A1 (0.64) | KMT2AALDH1A1MMP2ANPEPL3MBTL1 | |
| SCHEMBL8144145 | 0.88 | MMP1 (0.62) | ALDH1A1MMP2POLBMMP1MMP3 | |
| SCHEMBL8498279 | 0.88 | MMP1 (0.62) | ALDH1A1MMP2POLBMMP1MMP3 | |
| SCHEMBL9505317 | 0.88 | MMP2 (0.61) | KMT2AALDH1A1MMP2ANPEPMEN1 | |
| SCHEMBL5418227 | 0.88 | MMP2 (0.61) | KMT2AALDH1A1MMP2ANPEPMEN1 | |
| SCHEMBL5418223 | 0.88 | MMP2 (0.61) | KMT2AALDH1A1MMP2ANPEPMEN1 | |
| SCHEMBL17833288 | 0.88 | MMP2 (0.61) | KMT2AALDH1A1MMP2ANPEPMEN1 | |
| SCHEMBL541907 | 0.88 | ALDH1A1 (0.76) | KMT2AALDH1A1MMP2ANPEPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2008147800-A1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | KMT2A 4129/4885ALDH1A1 3733/4885MMP2 102/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | KMT2A 4129/4885ALDH1A1 3733/4885MMP2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.